B
Bloodscan develops and commercializes the Labyrinth automated CTC processor for non-invasive cancer diagnostics. This system utilizes advanced microfluidic technology for label-free, high-throughput enrichment of Circulating Tumor Cells (CTCs). The platform supports downstream applications like molecular characterization and personalized medicine through high-purity CTC isolation.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Bloodscan develops and commercializes the Labyrinth automated CTC processor for non-invasive cancer diagnostics. This system utilizes advanced microfluidic technology for label-free, high-throughput enrichment of Circulating Tumor Cells (CTCs). The platform supports downstream applications like molecular characterization and personalized medicine through high-purity CTC isolation.